Cell Line Development Market – By Products & Services (Reagents & Media, Equipment {Incubator, Bioreactors}), Source (Non-mammalian, Mammalian), Cell Line (Recombinant, Hybridoma), Application (Drug Discovery, Tissue Engineering), End-use – Global Forecast (2024 ­ 2032)

Cell Line Development Market Size

Cell Line Development Market size was valued at USD 5.8 billion in 2023 growing at a CAGR of 10.3% between 2024 and 2032. One of the primary drivers for the growth is the surging global prevalence of cancer owing to adoption of sedentary lifestyle, lack of physical exercise, consumption of harmful substances such as alcohol, tobacco, exposure to environmental pollutants and radiation.
 

 For instance, as per the report of the World Health Organization and International Agency for Research on Cancer (IARC) in February 2024, it has been reported that in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million.
 

Also, about 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women died from the disease. Thus, the rising incidence of cancer has created a greater need for early and accurate diagnosis of disease along with rising demand for the development of novel drug therapeutics which are the factors driving the demand for cell line products. Moreover, higher demand for vaccines and increasing awareness pertaining to monoclonal antibodies will accelerate the overall industry progress.
 

Cell line development (CLD) is a method that is utilized in a range of research and drug development and production applications such as identifying therapeutic targets and producing biologic drugs. The method starts with the selection of host cells and the most used host cell is HEK293 cells. Further, cell line development requires the discovery of clones derived from single cells that produce high and consistent levels of the target therapeutic protein.
 

Cell Line Development Market Trends

Advanced techniques such as CRISPR/Cas9 and other genome editing tools allow precise modifications to cell lines, leading to higher expression of desired proteins and improved productivity.
 

• For instance, in January 2023, Abzena announced the launch of AbZelect and AbZelectPRO, its new cell line development (CLD) platforms, designed to speed up the generation of production cell lines for the manufacture of antibodies and recombinant proteins. Thus, the introduction of technologically advanced cell line development tools such as reagents & media, and equipment is anticipated to propel the growth of market.
   

Moreover, innovations in cell line characterization and monitoring improve the quality and consistency of the cell lines, leading to more reliable and reproducible results in biomanufacturing that are further observed to drive the market growth.
 

Cell Line Development Market Analysis

Based on the products & services, the market is classified into reagents & media, equipment, accessories & consumables, and services. The reagents & media segment dominated the market with revenue of USD 2.6 billion in 2023.
 

• Recurring demand for media and reagents during the cell line development process along with surging R&D activities for drug discovery and development are a few aspects augmenting the segmental progression. Also, technological advancements such as the development of serum-free, chemically defined, and protein-free media, improve cell line productivity and consistency, thereby boosting the demand for specialized media and reagents.
   
• Furthermore, the expanding demand of stem cell therapy, which relies heavily on specific cell culture reagents and media, contributes to market growth.
   

Based on source, the global cell line development market is classified into mammalian and non-mammalian. The non-mammalian segment is further bifurcated into insects and amphibians. The mammalian segment dominated the market with market share of 72.3% in 2023.
 

• Mammalian cell lines are preferred to produce complex biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and vaccines due to their ability to perform complex post-translational modifications. Also, the increasing demand for biologics and biosimilars which require mammalian cell lines for their production is anticipated to propel the growth of the market.
   
• Further, innovations in cell culture media and reagents designed specifically for mammalian cell lines improve cell viability and productivity, thereby supporting market growth.
   

Based on cell line, the cell line development market is classified into recombinant, hybridomas, continuous cell line, and primary cell lines. The recombinant segment is expected to reach USD 4.1 billion by 2032.
 

• The increasing prevalence of cancer and growing need for therapeutic proteins, monoclonal antibodies, and vaccines drives the demand for recombinant cell lines which are essential for producing the biologics.
   
• Moreover, the increasing application of recombinant cell lines in developing personalized medicine, particularly for creating patient-specific cell lines for disease modeling and drug testing are the factors augmenting the market growth.
   

Based on application, the global cell line development market is classified into bioproduction, drug discovery, toxicity testing, tissue engineering, and research applications. The bioproduction segment dominated the market with market share of 45.6% in 2023.
 

• Cell lines are used in the bioproduction of vaccines, therapeutic proteins, and other biologics. Therefore, growing demand for vaccines, introduction of biosimilars and development of advanced processes for large scale biologics production will drive segment expansion.
   
• Furthermore, the increasing investments in bioprocessing infrastructure including the development of advanced bioreactors and scalable production systems, support the growth of the bioproduction segment.
   

Based on end-use, the cell line development market is classified into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations (CROs). The pharmaceutical & biotechnology companies segment is expected to exhibit 10.5% CAGR between 2024 - 2032.
 

• Pharmaceutical and biotechnology companies are significantly increasing their research and development (R&D) expenditures to develop new drugs and therapies. This drives the demand for cell line development as a critical step in the drug discovery and development process. Also, these companies are increasingly engaging in collaborations and partnerships to leverage their expertise in cell line development, thereby supplementing the segmental growth.
   
• Furthermore, pharmaceutical and biotechnology companies are expanding their operations globally, particularly in emerging markets, which increases the demand for localized cell line development capabilities to meet regional regulatory requirements and market needs. 
   

In 2023, North America secured a substantial market share of 34.3% in the global cell line development market and is expected to dominate throughout the forecast period.
 

• Huge patient base prone to infectious and chronic diseases, increasing demand for vaccines and various government initiatives in the region will drive the business progression. Also, the presence of leading biotechnology and pharmaceutical companies, as well as numerous research institutions and universities, fosters innovation and development in the field of cell line development.
   
• Further, government initiatives and funding, including grants from institutions such as the National Institutes of Health (NIH), support research in cell line development and related areas in U.S., thereby boosting the market growth.
   

Germany to experience the highest growth rate in the Europe cell line development market.
 

• Germany has a well-established regulatory framework for biotechnology and pharmaceuticals, which provides clear guidelines and standards for cell line development and ensures high-quality and safe products.
   
• Moreover, Germany is known for its advancements in biotechnology and healthcare technology. Therefore, country comprises several bio clusters and innovation hubs such as BioRN (Heidelberg), BioM (Munich), and others, which provide a conducive environment for biotechnology companies to thrive and innovate in cell line development, thereby fostering the market growth.
   

The Asia Pacific cell line development treatment market is expected to grow with a significant CAGR of 10.7% during the forecast period.
 

• The Asia Pacific cell line development market will witness a lucrative CAGR over the forecast period due to rising R&D expenditure and developments in pharmaceutical and biotechnology sectors. Also, several expansion strategies adopted by leading market participants will further accelerate industry growth.
   
• Moreover, increasing trend of outsourcing manufacturing services by pharmaceutical companies to CDMO/CMOs in countries such as India and China due to cost-effectiveness and specialized expertise will contributing to the growth of the market in this region.
   
• Furthermore, increased R&D activities in fields such as oncology, genetic disorders, and personalized medicine are fueling the need for specialized cell lines, thereby driving market growth.
   

Cell Line Development Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical & biotechnology companies that manufacture cell line development products vying for market share. Key players are engaging in strategic initiatives such as collaboration, product launch, investment, and partnerships to strengthen their product portfolio. The companies are actively adopting a multi-pronged approaches to address the rising demand for cell line development.
 

Cell Line Development Market Companies

Prominent players operating in the cell line development industry are as mentioned below:

• Advanced Instruments, LLC
• Aragen Life Sciences Ltd.
• ASIMOV
• Cytiva (Danaher Corporation)
• Eurofins Scientific
• Fyonibio
• GensSript Biotech
• Lonza Group AG
• Novartis AG
• ProBioGen
• PromoCell
• Sartorius AG
• Sigma Aldrich (Merck KGaA)
• Thermo Fisher Scientific Inc.
• WuXi AppTec
   

Cell Line Development Industry News:

• In November 2023, Lonza announced the launch of its new GS Effex cell line for the development of therapeutics antibodies with enhanced potency. The GS Effex cell line was developed to meet pressing market needs originating from the shift towards more sophisticated therapeutic antibodies. This helped the company expand its product offerings.
   
• In November 2022, QIAGEN Digital Insights (QDI), announced the launch of their new cell line database developed through its partnership with ATCC. This database offers manually curated sequencing data for standardized, authenticated, and reproducible cell lines. This product launch aimed to broaden the product availability for cell line development, complementing existing product portfolio.
   

The cell line development market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Products & Services

• Reagents & media
• Equipment
  • Incubators
  • Centrifuge
  • Bioreactors
  • Storage equipment
  • Microscopes
  • Electroporators
  • Fluorescence-activated cell sorting (FACS)
  • Other equipment
• Accessories and consumables
• Services

Market, By Source

• Mammalian
• Non-mammalian
  • Insects
  • Amphibians

Market, By Cell Line

• Recombinant
• Hybridomas
• Continuous cell lines
• Primary cell lines

Market, By Application

• Bioproduction
• Drug discovery
• Toxicity testing
• Tissue engineering
• Research applications

Market, By End-use

• Pharmaceutical and biotechnology companies
• Academic & research institutes
• Contract research organizations (CROs)

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudia Arabia
  • UAE
  • Rest of Middle East and Africa